ClinicalTrials.gg
CompletedNCT00655135Updated Apr 9, 2008

Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

A Phase 2 interventional study of LDP-02 and Placebo in Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-04-09.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
15th of 39
185 · median 101
Started
2000
the only one that year
Phase 2
7 of 39
1 open now
Registered
2nd of 39
by date
Lead sponsor
4 of 39
Millennium Pharmaceuticals, Inc.

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 15th largest by enrollment, is the only one that started in 2000, is one of 7 in phase 2, and was the 2nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce Crohn's disease activity, and to obtain pharmacokinetic (PK) and pharmacodynamic(PD)information for LDP-02 in patients with active Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80, nonhospitalized, male or nonpregnant, nonlactating females voluntarily able to give .
  • Crohn's disease of at least 6 months' duration.
  • Endoscopic and/or histopathological and/or radiological documentation consistent with Crohn's disease obtained preferably within 24 months of screening.
  • Crohn's disease involving the colon and/or the ileum.
  • CDAI score from 220 to 400 (inclusive) at the time of the Screening visit. The CDAI must have remained between 220 and 400 after the 1-week Screening period for the patient to be eligible.
  • Patients may have been receiving oral or topical 5-ASA compounds provided the dosage had been stable for at least the 14-day period before the Screening visit. Patients were to be maintained on the 5-ASA compound at a constant dose at least through Day 57.

Exclusion criteria

Exclusion Criteria:

  • Patients with evidence of current GI infection (bacterial or parasitic) or significant infection within 45 days of the screening visit.
  • Patients with a serious underlying disease other than Crohn's disease including presence or history of (except basal cell carcinoma) and histological evidence of dysplasia.
  • Patients with significantly impaired liver or renal function. This includes those with established chronic liver disease including or C.
  • Patients with the laboratory abnormalities
  • Patients using ethanol or consuming illicit drugs which, in the investigator's opinion, may interfere with compliance with the study procedures.
  • Patients with active psychiatric problems which, in the investigator's opinion, may interfere with compliance with the study procedures.
  • Patients who have previously received or who are currently receiving treatment with a monoclonal antibody.
  • Patients receiving any therapy, excluded medications as defined in protocol, or any approved therapy in an investigational protocol within 30 days prior to screening.
  • Patients unable to attend all the study visits or comply with study procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Placebo comparator
    1

    Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.

    Drug: Placebo

  • Experimental
    2

    Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.

    Drug: LDP-02

  • Experimental
    3

    Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.

    Drug: LDP-02

Interventions

  • DrugLDP-02

    Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.

    Also known as: MLN0002, MLN02

  • DrugPlacebo

    Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.

    Also known as: MLN0002, MLN02

06

What researchers measure

Primary outcomes

  1. The primary outcome measure was the proportion of patients with a clinical response, defined as a reduction from baseline in the CDAI score of at least 70 points at Day 57

    Time frame: Days 1-57

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Cohen A, Bitton A, Baker J, Dube R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370-7. doi: 10.1016/j.cgh.2008.06.007. Epub 2008 Oct 1. Erratum In: Clin Gastroenterol Hepatol. 2009 Apr;7(4):494. PubMed 18829392 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2000 and a primary completion of Jun 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2008
First posted
Apr 9, 2008
Start
Feb 2000
Primary completionActual
Jun 2002
Last update
Apr 9, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00655135
First posted
Apr 9, 2008
Start date
Feb 2000
Primary completion
Jun 2002
Last update
Apr 9, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion